Compare GNLN & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLN | VIVS |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Durable Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.9M |
| IPO Year | 2019 | N/A |
| Metric | GNLN | VIVS |
|---|---|---|
| Price | $3.28 | $1.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.5K | ★ 37.0K |
| Earning Date | 05-14-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,275,000.00 | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.01 | $1.13 |
| 52 Week High | $7.73 | $5.30 |
| Indicator | GNLN | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 30.77 |
| Support Level | $2.71 | N/A |
| Resistance Level | $3.50 | $1.38 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 71.15 | 6.77 |
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). It serves specialty retailers, smoke shops, head shops, convenience stores, and consumers. Geographically, it operates in United States, Canada, and Europe. It derives majority revenue from the United States. Its two operating segments are: Wholesale and Distribution, which includes legacy e-commerce and drop-ship operations; and Digital Assets, which includes digital asset treasury activities including acquisition, staking and validator participation related to BERA.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.